Biogaia Ab

The University of Texas System

Biogaia Biologies Ab

Infant Bacterial Therapeutics Ab

Ilya Pharma Ab

Stefan Roos

Bo Möllstam

Bo Mollstam

Eamonn Connolly

John Bienenstock

Wolfgang Kunze

Yuying Liu

Hans Jonsson

Evelina Vågesjö

Jon Marc Rhoads

Baokun He

Ivan Casas

Muhammed Khan

Estelle Grasset

Staffan Stromberg

Mia Phillipson

Muhammad Khan

Staffan STRÖMBERG

The invention relates to selection of bacterial strain for use in treating serotonin deficiency and/or a disease related to serotonin deficiency by culturing bacteria of a lactic acid producing bacterial strain, under aerobic conditions, in a culture medium comprising tryptophan. Any serotonin produced by the bacteria of the lactic acid producing bacterial strain in the culture medium is detected and the lactic acid producing bacterial strain is selected as effective in treating serotonin deficiency and/or a disease related to serotonin deficiency in a subject if serotonin is detected in the culture medium.

Serotonin producing bacteria

The present invention relates to methods of activating live lactic acid bacteria comprising exposing said bacteria to a preparation comprising citrate, wherein said bacteria have the ability to utilize citrate as an external electron acceptor. The present invention further relates to methods to enhance the activity of certain live bacteria in mammals. More specifically the invention relates to improve the wake-up of certain lactic acid bacteria from the freeze-dried state. The present invention also relates to preparations comprising said activated bacteria and therapeutic uses of said activated bacteria.

Method of activating lactic acid bacteria

The present invention relates to lactic acid bacterial strains which are capable of producing or inducing the production of melatonin, for use in the production of melatonin in a subject. Preferred strains for such uses are capable of producing or inducing the production of adenosine. Therapeutic uses of such strains include the treatment or prevention of diseases associated with melatonin deficiency, for example infantile colic. Novel strains are also provided.

Selection and use of melatonin supporting bacteria to reduce infantile colic

A method to provide therapeutic microvesicles from probiotic bacteria comprises exposing the bacteria to an inducing treatment during culturing to induce production of therapeutic microvesicles by the bacteria. The therapeutic microvesicles may be used in treatment of, for instance, colic, an infant or childhood gastrointestinal disorder or disease, a gastrointestinal pain disorder, a bone loss disease and/or a periodontal disease.

Therapeutic microvesicles of probiotic bacteria

The present invention relates to novel strains of lactic acid bacteria, more specifically, novel strains of, capable of utilizing ethanolamine. This characteristic makes it possible for the bacteria to compete for the same substrate as pathogenic ethanolamine-utilizing pathogens, thereby presenting an effective means to combat infections resulting from such pathogenic bacteria. There is also provided a method of selecting further ethanolamine-utilizing lactic acid bacteria, as well as other methods and uses involving said novel strains and other ethanolamine-utilizing lactic acid bacteria.

Lactic acid bacteria, methods and uses thereof

The present invention provides the use of inosine in the treatment of a disease associated with Treg deficiency or Treg dysfunction, in particular immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX). In one embodiment of the invention, the inosine can be provided in the form of a bacterial strain that is capable of stimulating the production of inosine. Methods for stimulating the production of inosine in a subject using said strains are also provided, as are methods for the selection of a bacterial strain capable of stimulating inosine production in a subject.

Use of inosine for the treatment of t-reg deficiency

The present invention relates to novel strains of lactic acid bacteria, more specifically, novel strains ofcapable of utilizing ethanolamine. This characteristic makes it possible for the bacteria to compete for the same substrate as pathogenic ethanolamine-utilizing pathogens, thereby presenting an effective means to combat infections resulting from such pathogenic bacteria. There is also provided a method of selecting further ethanolamine-utilizing lactic acid bacteria, as well as other methods and uses involving said novel strains and other ethanolamine-utilizing lactic acid bacteria.

Methods for the controlled activation of the reuterin-production machinery ofby adding glycerol and other substances during the manufacture of cell-cultures and keeping the produced reuterin in the bacterial cell during preservation and storage. In particular this invention relates to the manufacture of large amounts ofthat are loaded with reuterin, and the use of such loaded bacteria for applications

[object Object]

Methods for the controlled activation of the reuterin-production machinery ofby adding glycerol and other substances during the manufacture of cell-cultures and keeping the produced reuterin in the bacterial cell during preservation and storage. In particular this invention relates to the manufacture of large amounts ofthat are loaded with reuterin, and the use of such loaded bacteria for applications such as prevention and treatment of diseases, for food applications and the like.

Live vaccines and methods for preparing the vaccines useful in protecting a host from infection by a pathogenic microorganism are provided. Vaccines are prepared from live Lactobacillus cells which have been transformed using DNA technology to express heterologous antigens of pathogenic microorganisms or other suitable biological material. Genes encoding antigenic determinants pathogenic in the mammalian gastrointestinal tract are inserted into expression cassettes and fused with genes encoding an aggregation factor and/or a mucin binding factor. The inserted genes are shown to transform L. reuteri cells. The aggregation enhancing and mucin binding genes have been isolated and sequenced. The vaccine can be ingested orally in a pharmaceutical carrier or in milk products.

Growing community of inventors

Uppsala, Sweden

Stefan Roos